Copyright
©The Author(s) 2024.
World J Stem Cells. Jun 26, 2024; 16(6): 641-655
Published online Jun 26, 2024. doi: 10.4252/wjsc.v16.i6.641
Published online Jun 26, 2024. doi: 10.4252/wjsc.v16.i6.641
Table 14 Medical Research Council muscle strength scale left values of each patient
| MRC muscle strength scale (left) | ||||||
| Pre-test | Post-test (1st wk) | Post-test (1st month) | Post-test (2nd month) | Post-test (4th month) | Post-test (12th month) | |
| Patient 1 | 2 | 2 | 2 | 3 | 3 | 3 |
| Patient 2 | 2 | 2 | 3 | 3 | 3 | 4 |
| Patient 3 | 5 | 5 | 5 | 5 | 5 | 5 |
| Patient 4 | 1 | 1 | 2 | 3 | 3 | 3 |
| Patient 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Patient 6 | 5 | 5 | 5 | 5 | 5 | 5 |
- Citation: Kabatas S, Civelek E, Boyalı O, Sezen GB, Ozdemir O, Bahar-Ozdemir Y, Kaplan N, Savrunlu EC, Karaöz E. Safety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study. World J Stem Cells 2024; 16(6): 641-655
- URL: https://www.wjgnet.com/1948-0210/full/v16/i6/641.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i6.641